Lv1
30 积分 2024-01-08 加入
Zipalertinib—A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR Mutations
9天前
已完结
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
9天前
已完结
PROTAC approaches against drug-resistant EGFRC797S/L858R/T790M mutants: biological evaluation and SAR studies (2020–2025)
10天前
已完结
HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer
10天前
已完结
Design, synthesis, and biological evaluation of novel probe-quality EGFR degraders targeting wild-type and Del19 mutation
10天前
已关闭
Divergent Asymmetric Total Synthesis of the cis-Clerodane Diterpenoids
17天前
已完结
Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual Inhibitor
26天前
已完结
Discovery of Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors for Cancer Therapy
26天前
已完结
Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- b ]indole Derivatives with Potent Activity against Multidrug-Resistant Gram-Negative Bacteria
1个月前
已完结
From KRAS G12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
1个月前
已完结
皖公网安备34019202002308
